摘要
目的:探讨EGFR在胃癌耐药细胞中的表达及作用。方法:采用Western blot和免疫组化检测EGFR蛋白在胃癌耐药细胞系及组织标本中的表达,WST-1检测EGFR特异性抗体Cetuximab对胃癌耐药细胞增殖及化疗敏感性的影响。结果:SGC7901/ADR胃癌耐药细胞系中EGFR的表达明显高于亲本细胞,多数化疗后进展的胃癌组织EGFR的表达高于化疗前组织,针对EGFR的单克隆抗体Cetuximab可抑制SGC7901/ADR细胞的增殖,并增加其对部分化疗药物的敏感性。结论:EGFR过表达是胃癌细胞化疗耐药的分子机制之一,Cetuximab可逆转EGFR高表达耐药细胞的耐药表型。
Objective： To investigate the function and significance of EGFR expression in chemo-refractory gastric cancer（GC） cell lines.Method： Three human gastric cancer cell lines（SGC7901,SGC7901/ADR,SGC7901/VCR） were selected.SGC7901/ADR and SGC7901/VCR were adriamycin-resistant and vincristine-resistant GC cell lines respectively,with the same parental cell line SGC7901.All the three cell lines were evaluated for cell surface EGFR expression by western blot analysis and immunohistochemistry staining.Cells were treated with varying concentrations of cetuximab.The biological endpoint was cell viability and chemo-sensitivity,which was measured by WST-1 proliferation assay.Corresponding data were evaluated via statistical methods.Results： EGFR expression was noticed to be much higher in chemo-refractory GC cell line SGC7901/ADR,compared with the parental cell SGC7901.In addition,tissues from patients bearing disease progression after chemotherapy revealed stronger EGFR levels.Furthermore,it was found that cetuximab suppresses the proliferation and enhances chemo-sensitivity of SGC7901/ADR.Conclusion： EGFR overexpression is supposed to be one of the leading causes of chemo-refraction.The data indicate that cetuximab may also serve as an evidence for reversing chemo-refractory phenotype in GC.
出处
《现代生物医学进展》
CAS
2013年第12期2253-2256,2264,共5页
Progress in Modern Biomedicine
基金
国家重点基础发展计划项目973计划(2009CB521705)
关键词
西妥昔单抗
胃癌
化疗耐药
Cetuximab
Gastric cancer
Chemo-refractory
